[Treatment of peptic ulcer and gastritis associated with Helicobacter pylori].
López-Brea
M
M
Servicio de Microbiología, Hospital de la Princesa, Madrid.
Alarcón
T
T
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002908:Chronic Disease; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004382:Duodenitis / Q000188:drug therapy / Q000382:microbiology; D005756:Gastritis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects / Q000472:pathogenicity; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000209:etiology; D008795:Metronidazole / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000209:etiology; D012459:Salicylates / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000209:etiology
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009942:Organometallic Compounds; D012459:Salicylates; D008795:Metronidazole; C015715:bismuth subsalicylate; D001729:Bismuth
Tratamiento de la úlcera péptica y la gastritis asociada a Helicobacter pylori.